Skip to main content
Authored Items
Safety of Inactivated Vaccines in Patients Receiving Immune Checkpoint Inhibitors
Austin Kurkowski, PharmD, BCOP, Grace A. Martin, PharmD, BCOP, Shelbie Ralph, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Elizabeth Wulff-Burchfield, MD
JHOP - August 2021 Vol 11, No 4 in Original Article, Vaccinations, Checkpoint Inhibitors
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD, Beth Eddy, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4 in Original Article, Transplant, Leukemia, Myelodysplastic Syndromes, Conditioning Regimen
Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience
Vincent J. Cascone, PharmD, BCOP, Kane M. Hosmer, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, David W. Henry, MS, RPh, BCOP, FASHP, Dennis W. Grauer, MS, PhD
JHOP - December 2020 Vol 10, No 6 in Original Article, Chemotherapy
Risk Factors for Subtherapeutic Tacrolimus Levels After Conversion from Intravenous to Oral Dosing Posttransplant in Adults
Kelsey Konrardy, PharmD, Kane M. Hosmer, PharmD, BCOP, Michelle Rockey, PharmD, BCOP, FHOPA, Zahra Mahmoudjafari, PharmD, BCOP, Dennis W. Grauer, MS, PhD, David W. Henry, MS, RPh, BCOP, FASHP, Leyla Shune, MD, Joseph McGuirk, DO
JHOP - June 2020 Vol 10, No 3 in Original Article, Transplant
Last modified: January 15, 2021